Robert A Bonomo

List of Publications by Year
in descending order

336 papers	24,719 citations	11235 73 h-index	10679 143 g-index
357 all docs	357 docs citations	357 times ranked	18591 citing authors

#	Article	IF	Citations
1	The urgent need for metallo-Î²-lactamase inhibitors: an unattended global threat. Lancet Infectious Diseases, The, 2022, 22, e28-e34.	4.6	103
2	Association of a geriatric emergency department program with healthcare outcomes among veterans. Journal of the American Geriatrics Society, 2022, 70, 601-608.	1.3	17
3	Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infectious Diseases, The, 2022, 22, 401-412.	4.6	122
4	Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane Î²-Lactamase Inhibitor To Augment Î²-Lactam Action. MBio, 2022, 13, e0352921.	1.8	13
5	Staphylococcus aureus and Acinetobacter baumannii Inhibit Osseointegration of Orthopedic Implants. Infection and Immunity, 2022, 90, iai0066921.	1.0	7
6	Accuracy of Direct Antimicrobial Susceptibility Testing of Gram-Negative Bacteria from Positive Blood Cultures Using MicroScan System and Value of Using Expert Rules for Î²-Lactam Agents. Antimicrobial Agents and Chemotherapy, 2022, 66, aac0214821.	1.4	2
7	Deciphering the evolution of metallo-Î²-lactamases: A journey from the test tube to the bacterial periplasm. Journal of Biological Chemistry, 2022, 298, 101665.	1.6	21
8	An Analysis of the Novel Fluorocycline TP-6076 Bound to Both the Ribosome and Multidrug Efflux Pump AdeJ from Acinetobacter baumannii. MBio, 2022, 13, e0373221.	1.8	13
9	European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European) Tj ETQq1 1 0.784314 rgBT /Overlock	2.4	312
10	Infectious Diseases Society of America Guidance on the Treatment of AmpC Î²-Lactamaseâ€“Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clinical Infectious Diseases, 2022, 74, 2089-2114.	2.9	262
11	Clinical challenges treatingStenotrophomonas maltophiliainfections: an update. JAC-Antimicrobial Resistance, 2022, 4, dlac040.	0.9	39
12	Discovery of an Effective Small-Molecule Allosteric Inhibitor of New Delhi Metallo-Î²-lactamase (NDM). ACS Infectious Diseases, 2022, 8, 811-824.	1.8	4
13	Structural Characterization of the D179N and D179Y Variants of KPC-2 Î²-Lactamase: Î©-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2022, 66, e0241421.	1.4	22
14	Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX. MBio, 2022, 13, e0049722.	1.8	17
15	Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2022, 66, e0212421.	1.4	11
16	Human Serum Proteins and Susceptibility of Acinetobacter baumannii to Cefiderocol: Role of Iron Transport. Biomedicines, 2022, 10, 600.	1.4	8
17	Genomic heterogeneity underlies multidrug resistance in Pseudomonas aeruginosa: A population-level analysis beyond susceptibility testing. PLoS ONE, 2022, 17, e0265129.	1.1	13
18	mBio Welcomes Clinical Research Papers That Advance Our Understanding of Human-Microbe Interactions. MBio, 2022, , e0052722.	1.8	0

#	Article	IF	Citations
19	Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance. MBio, 2022, 13, e0275921.	1.8	27
20	Consensus on Î²-Lactamase Nomenclature. Antimicrobial Agents and Chemotherapy, 2022, 66, e0033322.	1.4	11
21	Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant Î²-Lactamases and Their Increasing Importance. Antimicrobial Agents and Chemotherapy, 2022, 66, e0179021.	1.4	8
22	Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2022, 75, 187-212.	2.9	182
23	A Tribute to George A. Jacoby. Antimicrobial Agents and Chemotherapy, 2022, , e0049822.	1.4	0
24	Acinetobacter baumannii response to cefiderocol challenge in human urine. Scientific Reports, 2022, 12, .	1.6	9
25	Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT): A Framework for Assessing Antibiotic Selection Strategies in the Presence of Drug Resistance. Clinical Infectious Diseases, 2021, 73, 344-350.	2.9	13
26	A comprehensive and contemporary â€œsnapshotâ€•of Î²-lactamases in carbapenem resistant Acinetobacter baumannii. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115242.	0.8	16
27	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2021, 72, e169-e183.	2.9	292
28	Natural variants modify Klebsiella pneumoniae carbapenemase (KPC) acylâ€“enzyme conformational dynamics to extend antibiotic resistance. Journal of Biological Chemistry, 2021, 296, 100126.	1.6	27
29	Cerebrospinal fluid (CSF) augments metabolism and virulence expression factors in Acinetobacter baumannii. Scientific Reports, 2021, 11, 4737.	1.6	16
30	Structural Characterization of Diazabicyclooctane Î²-Lactam â€œEnhancersâ€•in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa. MBio, 2021, 12, .	1.8	19
31	Structural and Biochemical Characterization of the Novel CTX-M-151 Extended-Spectrum Î²-Lactamase and Its Inhibition by Avibactam. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	5
32	Carbapenem Use Is Driving the Evolution of Imipenemase 1 Variants. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	13
33	Allosteric communication in class A Î²-lactamases occurs via cooperative coupling of loop dynamics. ELife, 2021, 10, .	2.8	44
34	Risk Factors for and Mechanisms of COlistin Resistance Among Enterobacterales: Getting at the CORE of the Issue. Open Forum Infectious Diseases, 2021, 8, ofab145.	0.4	8
35	Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum Î²-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), andPseudomonas aeruginosawith Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clinical Infectious Diseases, 2021, 72, 1109-1116.	2.9	251
36	Human Pleural Fluid and Human Serum Albumin Modulate the Behavior of a Hypervirulent and Multidrug-Resistant (MDR) Acinetobacter baumannii Representative Strain. Pathogens, 2021, 10, 471.	1.2	17

#	Article	IF	Citations
37	Monoclonal Antibody Requires Immunomodulation for Efficacy Against Acinetobacter baumannii Infection. Journal of Infectious Diseases, 2021, 224, 2133-2147.	1.9	12
38	Cryo-EM Determination of Eravacycline-Bound Structures of the Ribosome and the Multidrug Efflux Pump AdeJ of Acinetobacter baumannii. MBio, 2021, 12, e0103121.	1.8	29
39	Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed bla _{PDC} in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	8
40	Detection of mcr-1 gene in a clinical Escherichia coli strain in North Carolina: first report. Journal of Global Antimicrobial Resistance, 2021, 25, 154-156.	0.9	1
41	â€œOne-Two Punchâ€• Synergistic ÃŸ-Lactam Combinations forMycobacterium abscessusand Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. Clinical Infectious Diseases, 2021, 73, 1532-1536.	2.9	15
42	Interaction of Acinetobacter baumannii with Human Serum Albumin: Does the Host Determine the Outcome?. Antibiotics, 2021, 10, 833.	1.5	5
43	2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo-Î²-Lactamase Classes by Maintaining a Conserved Binding Mode. ACS Infectious Diseases, 2021, 7, 2697-2706.	1.8	16
44	A Î³-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.. European Journal of Medicinal Chemistry, 2021, 220, 113436.	2.6	14
45	Involvement of the Histone-Like Nucleoid Structuring Protein (H-NS) in Acinetobacter baumanniiâ€™s Natural Transformation. Pathogens, 2021, 10, 1083.	1.2	4
46	Specific Protein-Membrane Interactions Promote Packaging of Metallo-Î²-Lactamases into Outer Membrane Vesicles. Antimicrobial Agents and Chemotherapy, 2021, 65, e0050721.	1.4	10
47	Monoclonal Antibody Therapy against Acinetobacter baumannii. Infection and Immunity, 2021, 89, e0016221.	1.0	17
48	On the Offensive: the Role of Outer Membrane Vesicles in the Successful Dissemination of New Delhi Metallo-Î²-lactamase (NDM-1). MBio, 2021, 12, e0183621.	1.8	17
49	The Role of Hydrophobic Nodes in the Dynamics of Class A Î²-Lactamases. Frontiers in Microbiology, 2021, 12, 720991.	1.5	6
50	Histone-like nucleoid-structuring protein (H-NS) regulatory role in antibiotic resistance in Acinetobacter baumannii. Scientific Reports, 2021, 11, 18414.	1.6	8
51	Interplay between Meropenem and Human Serum Albumin on Expression of Carbapenem Resistance Genes and Natural Competence in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2021, 65, e0101921.	1.4	10
52	2-Mercaptomethyl-thiazolidines use conserved aromaticâ€“S interactions to achieve broad-range inhibition of metallo-Î²-lactamases. Chemical Science, 2021, 12, 2898-2908.	3.7	24
53	Orthopedic Implant-Associated and Central Venous Catheter-Associated Infections Caused by Microbacterium spp. in the Veterans Affairs Healthcare System from 2000 to 2020. Surgical Infections, 2021, , .	0.7	1
54	Structural analysis of the boronic acid Î²-lactamase inhibitor vaborbactam binding to Pseudomonas aeruginosa penicillin-binding protein 3. PLoS ONE, 2021, 16, e0258359.	1.1	9

#	Article	IF	Citations
55	The BioWipe: a non-invasive method to detect intestinal carriage of multi-drug resistant gram-negative bacteria. Journal of Chemotherapy, 2021, , 1-3.	0.7	1
56	Carbapenemaseâ€producing Enterobacterales in solid organ transplantation: Tip of the iceberg?. Transplant Infectious Disease, 2021, , .	0.7	1
57	OXA-23 Î²-Lactamase Overexpression in Acinetobacter baumannii Drives Physiological Changes Resulting in New Genetic Vulnerabilities. MBio, 2021, 12, e0313721.	1.8	10
58	The Pitt Bacteremia Score Predicts Mortality in Nonbacteremic Infections. Clinical Infectious Diseases, 2020, 70, 1826-1833.	2.9	52
59	Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clinical Infectious Diseases, 2020, 71, 304-310.	2.9	126
60	A Standard Numbering Scheme for Class C Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	50
61	Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemaseâ€“4 and New Delhi Metallo-Î²-Lactamaseâ€“1. Clinical Infectious Diseases, 2020, 71, 1095-1098.	2.9	59
62	Characterisation of ST25 NDM-1-producing Acinetobacter spp. strains leading the increase in NDM-1 emergence in Argentina. Journal of Global Antimicrobial Resistance, 2020, 23, 108-110.	0.9	9
63	Structural Insights into Inhibition of the Acinetobacter-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State Analog. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
64	Efflux pumps as interventions to control infection caused by drug-resistance bacteria. Drug Discovery Today, 2020, 25, 2307-2316.	3.2	17
65	Overview. Infectious Disease Clinics of North America, 2020, 34, 649-658.	1.9	22
66	Resistance to Novel Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations. Infectious Disease Clinics of North America, 2020, 34, 773-819.	1.9	76
67	AbGRI4, a novel antibiotic resistance island in multiply antibiotic-resistant Acinetobacter baumannii clinical isolates. Journal of Antimicrobial Chemotherapy, 2020, 75, 2760-2768.	1.3	18
68	Genomic epidemiology of colistin-resistant Escherichia coli in China. Lancet Microbe, The, 2020, 1, e51-e52.	3.4	1
69	Predicting Î²-lactam resistance using whole genome sequencing in Klebsiella pneumoniae: the challenge of Î²-lactamase inhibitors. Diagnostic Microbiology and Infectious Disease, 2020, 98, 115149.	0.8	3
70	The H-NS Regulator Plays a Role in the Stress Induced by Carbapenemase Expression in Acinetobacter baumannii. MSphere, 2020, 5, .	1.3	10
71	The Ongoing Threat of Antimicrobial Resistance. Infectious Disease Clinics of North America, 2020, 34, xiii-xiv.	1.9	4
72	Drug-Resistant Tuberculosis. Infectious Disease Clinics of North America, 2020, 34, 863-886.	1.9	9

#	Article	IF	Citations
73	Structural Insights into Ceftobiprole Inhibition of Pseudomonas aeruginosa Penicillin-Binding Protein 3. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	9
74	A Î³-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. Journal of Medicinal Chemistry, 2020, 63, 5990-6002.	2.9	20
75	Carbapenemases: Transforming Acinetobacter baumannii into a Yet More Dangerous Menace. Biomolecules, 2020, 10, 720.	1.8	124
76	Insights into the <scp>l</scp> , <scp>d</scp> -Transpeptidases and <scp>d</scp> , <scp>d</scp> -Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	22
77	Î±â€Triazolylboronic Acids: A Promising Scaffold for Effective Inhibitors of KPCs. ChemMedChem, 2020, 15, 1283-1288.	1.6	1
78	Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. Journal of Antimicrobial Chemotherapy, 2020, 75, 2622-2632.	1.3	39
79	1,2,3-Triazolylmethaneboronate: A Structure Activity Relationship Study of a Class of Î²-Lactamase Inhibitors against Acinetobacter baumannii Cephalosporinase. ACS Infectious Diseases, 2020, 6, 1965-1975.	1.8	12
80	Cryo-electron Microscopy Structure of the Acinetobacter baumannii 70S Ribosome and Implications for New Antibiotic Development. MBio, 2020, 11, .	1.8	25
81	Structures of FOX-4 Cephamycinase in Complex with Transition-State Analog Inhibitors. Biomolecules, 2020, 10, 671.	1.8	4
82	Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infectious Diseases, The, 2020, 20, 731-741.	4.6	174
83	Colistin resistance in China: from outer membrane to One Health. Lancet Infectious Diseases, The, 2020, 20, 1106-1108.	4.6	3
84	Shedding of multidrug-resistant gram-negative bacilli by colonized patients during procedures and patient care activities. American Journal of Infection Control, 2020, 48, 1336-1340.	1.1	7
85	Core genome MLST and resistome analysis of Klebsiella pneumoniae using a clinically amenable workflow. Diagnostic Microbiology and Infectious Disease, 2020, 97, 114996.	0.8	6
86	Distinct Mechanisms of Dissemination of NDM-1 Metallo-Î²-Lactamase in Acinetobacter Species in Argentina. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	25
87	ARGONAUT II Study of the In Vitro Activity of Plazomicin against Carbapenemase-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	11
88	Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations. Clinical Infectious Diseases, 2019, 68, 519-524.	2.9	118
89	Human Pleural Fluid Elicits Pyruvate and Phenylalanine Metabolism in Acinetobacter baumannii to Enhance Cytotoxicity and Immune Evasion. Frontiers in Microbiology, 2019, 10, 1581.	1.5	30
90	Protein determinants of dissemination and host specificity of metallo-Î²-lactamases. Nature Communications, 2019, 10, 3617.	5.8	56

#	Article	IF	Citations
91	Identification of Potential Virulence Factors in the Model Strain Acinetobacter baumannii A118. Frontiers in Microbiology, 2019, 10, 1599.	1.5	28
92	External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. International Journal of Antimicrobial Agents, 2019, 54, 442-448.	1.1	11
93	Identification of four patients with colistin-resistant Escherichia coli containing the mobile colistin resistance mcr-1 gene from a single health system in Michigan. Infection Control and Hospital Epidemiology, 2019, 40, 1059-1062.	1.0	15
94	Natural history of Acinetobacter baumannii infection in mice. PLoS ONE, 2019, 14, e0219824.	1.1	26
95	Structural Insights into the Inhibition of the Extended-Spectrum Î²-Lactamase PER-2 by Avibactam. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	11
96	Population Structure, Molecular Epidemiology, and Î²-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States. MBio, 2019, 10, .	1.8	52
97	Cryo-Electron Microscopy Structure of an Acinetobacter baumannii Multidrug Efflux Pump. MBio, 2019, 10, .	1.8	56
98	Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. Journal of Antimicrobial Chemotherapy, 2019, 74, 3497-3504.	1.3	24
99	A Multi-Centered Case-Case-Control Study of Factors Associated With Klebsiella pneumoniae Carbapenemase-Producing Enterobacteriaceae Infections in Children and Young Adults. Pediatric Infectious Disease Journal, 2019, 38, 490-495.	1.1	17
100	Antibiotic collateral sensitivity is contingent on the repeatability of evolution. Nature Communications, 2019, 10, 334.	5.8	135
101	A Primer on AmpC Î²-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World. Clinical Infectious Diseases, 2019, 69, 1446-1455.	2.9	148
102	Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone Î²-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. MBio, 2019, 10, .	1.8	64
103	Rapid Replacement of Acinetobacter baumannii Strains Accompanied by Changes in Lipooligosaccharide Loci and Resistance Gene Repertoire. MBio, 2019, 10, .	1.8	28
104	Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens. Clinical Infectious Diseases, 2019, 69, S519-S520.	2.9	37
105	Human pleural fluid triggers global changes in the transcriptional landscape of Acinetobacter baumannii as an adaptive response to stress. Scientific Reports, 2019, 9, 17251.	1.6	27
106	A Single Salt Bridge in VIM-20 Increases Protein Stability and Antibiotic Resistance under Low-Zinc Conditions. MBio, 2019, 10, .	1.8	16
107	1H, 13C, and 15N backbone resonance assignments for KPC-2, a class A serine-Î²-lactamase. Biomolecular NMR Assignments, 2019, 13, 139-142.	0.4	2
108	Interspecies DNA acquisition by a naturally competent Acinetobacter baumannii strain. International Journal of Antimicrobial Agents, 2019, 53, 483-490.	1.1	14

#	Article	IF	Citations
109	The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2019, 6, ofy351.	0.4	11
110	The Reaction Mechanism of Metallo-Î²-Lactamases Is Tuned by the Conformation of an Active-Site Mobile Loop. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	26
111	Human fluids alter DNA-acquisition in Acinetobacter baumannii. Diagnostic Microbiology and Infectious Disease, 2019, 93, 183-187.	0.8	20
112	New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	208
113	ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum Î²-Lactamases and Carbapenemases. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	81
114	Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV. Clinical Infectious Diseases, 2019, 68, 1823-1830.	2.9	37
115	It's too soon to pull the plug on antibiotic cycling. Lancet Infectious Diseases, The, 2018, 18, 493.	4.6	4
116	The Continuing Challenge of Metallo-Î²-Lactamase Inhibition: Mechanism Matters. Trends in Pharmacological Sciences, 2018, 39, 635-647.	4.0	113
117	Relebactam Is a Potent Inhibitor of the KPC-2 Î²-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	74
118	Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using Î²-Lactamase Inhibitors and Î²-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. Journal of Medicinal Chemistry, 2018, 61, 4067-4086.	2.9	117
119	DISC: Describing Infections of the Spine treated with Ceftaroline. Journal of Global Antimicrobial Resistance, 2018, 13, 146-151.	0.9	7
120	New Molecular Diagnostic Approaches to Bacterial Infections and Antibacterial Resistance. Annual Review of Medicine, 2018, 69, 379-394.	5.0	58
121	Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxins. Diagnostic Microbiology and Infectious Disease, 2018, 91, 89-92.	0.8	10
122	Molecular characterisation of carbapenem-resistant Enterobacter cloacae complex in Colombia: bla KPC and the â€˜changing landscapeâ€™. Journal of Global Antimicrobial Resistance, 2018, 13, 184-189.	0.9	8
123	Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward â€˜molecularly targetedâ€™ therapy. Expert Review of Anti-Infective Therapy, 2018, 16, 89-110.	2.0	58
124	Carbapenemase-Producing Organisms: A Global Scourge. Clinical Infectious Diseases, 2018, 66, 1290-1297.	2.9	397
125	An Analysis of the Epidemic of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Convergence of Two Evolutionary Mechanisms Creates the â€œPerfect Stormâ€. Journal of Infectious Diseases, 2018, 217, 82-92.	1.9	70
126	Probing the Interaction of Aspergillomarasmine A with Metallo-Î²-lactamases NDM-1, VIM-2, and IMP-7. ACS Infectious Diseases, 2018, 4, 135-145.	1.8	48

#	Article	IF	Citations
127	Clinical Evolution of New Delhi Metallo-Î²-Lactamase (NDM) Optimizes Resistance under Zn(II) Deprivation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	64
128	Multiple substitutions lead to increased loop flexibility and expanded specificity in Acinetobacter baumannii carbapenemase OXA-239. Biochemical Journal, 2018, 475, 273-288.	1.7	16
129	Structure-Based Analysis of Boronic Acids as Inhibitors of Acinetobacter-Derived Cephalosporinase-7, a Unique Class C Î²-Lactamase. ACS Infectious Diseases, 2018, 4, 325-336.	1.8	30
130	Inhibition of Acinetobacter-Derived Cephalosporinase: Exploring the Carboxylate Recognition Site Using Novel Î²-Lactamase Inhibitors. ACS Infectious Diseases, 2018, 4, 337-348.	1.8	27
131	2267. The Effect of Opportunistic Infection (OI) Prophylaxis on the Gastrointestinal Microbiome (GIM) and Immune Reconstitution (IR) in Veterans With HIV and AIDS. Open Forum Infectious Diseases, 2018, 5, S671-S671.	0.4	0
132	698. Nacubactam Inhibits Class A Î²-lactamases. Open Forum Infectious Diseases, 2018, 5, S251-S252.	0.4	0
133	2336. Resistance Mechanisms and Factors Associated With CTX-M-9 Group Extended-Spectrum Î²-Lactamase (ESBL)-Producing Enterobacteriaceae Infections in Children. Open Forum Infectious Diseases, 2018, 5, S694-S694.	0.4	0
134	700. Identification and Whole-Genome Sequencing (WGS) of Meropenem-Vaborbactam (MV) Resistant Klebsiella pneumoniae (MVRKP) Among Patients Without Prior Exposure to MV: Collateral Damage. Open Forum Infectious Diseases, 2018, 5, S252-S252.	0.4	0
135	2385. Ceftazidimeâ€“Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. Open Forum Infectious Diseases, 2018, 5, S711-S711.	0.4	1
136	Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa. MBio, 2018, 9, .	1.8	61
137	Human serum albumin alters specific genes that can play a role in survival and persistence in Acinetobacter baumannii. Scientific Reports, 2018, 8, 14741.	1.6	47
138	Epidemiology of Carbapenem-Resistant Enterobacteriaceae at a Long-term Acute Care Hospital. Open Forum Infectious Diseases, 2018, 5, ofy224.	0.4	9
139	Defining the architecture of KPC-2 Carbapenemase:Âidentifying allosteric networks to fight antibiotics resistance. Scientific Reports, 2018, 8, 12916.	1.6	27
140	Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection Caused by Klebsiella pneumoniae Carbapenemaseâ€“Producing Klebsiella pneumoniae. Open Forum Infectious Diseases, 2018, 5, ofy054.	0.4	11
141	Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine Î²-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches. Frontiers in Microbiology, 2018, 9, 622.	1.5	28
142	A Noncanonical Metal Center Drives the Activity of the Sediminispirochaeta smaragdinae Metallo-Î²-lactamase SPS-1. Biochemistry, 2018, 57, 5218-5229.	1.2	11
143	In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	23
144	Evolution of New Delhi metallo-Î²-lactamase (NDM) in the clinic: Effects of NDM mutations on stability, zinc affinity, and mono-zinc activity. Journal of Biological Chemistry, 2018, 293, 12606-12618.	1.6	79

#	Article	IF	Citations
145	Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: Laboratory Detection and Impact on Mortality. Clinical Infectious Diseases, 2017, 64, ciw805.	2.9	150
146	Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-Î²-lactamase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw513.	1.3	46
147	Transcriptome Remodeling of Acinetobacter baumannii during Infection and Treatment. MBio, 2017, 8, .	1.8	53
148	Can Ceftazidime-Avibactam and Aztreonam Overcome Î²-Lactam Resistance Conferred by Metallo-Î²-Lactamases in Enterobacteriaceae?. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	217
149	Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime forBurkholderia cepaciaComplex Isolates from Cystic Fibrosis Patients. ACS Infectious Diseases, 2017, 3, 502-511.	1.8	62
150	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	4.6	367
151	The ecology of extended-spectrum Î²-lactamases (ESBLs) in the developed world. Journal of Travel Medicine, 2017, 24, S44-S51.	1.4	182
152	Simple Screening for Carbapenemase-Producing Enterobacteriaceae by Moxalactam Susceptibility Testing. Journal of Clinical Microbiology, 2017, 55, 2276-2279.	1.8	2
153	Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases, 2017, 64, S41-S47.	2.9	23
154	Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases, 2017, 64, S30-S35.	2.9	114
155	A cold hard menace: A contaminated ice machine as a potential source for transmission of carbapenem-resistant Acinetobacter baumannii. American Journal of Infection Control, 2017, 45, 1273-1275.	1.1	8
156	Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	14
157	WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent â€œÎ²-Lactam Enhancerâ€• Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-Î²-Lactamase-Producing High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	92
158	Exploring the potential of boronic acids as inhibitors of OXAâ€24/40 Î²â€lactamase. Protein Science, 2017, 26, 515-526.	3.1	30
159	Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clinical Microbiology Reviews, 2017, 30, 409-447.	5.7	773
160	Influence of Aging and Environment on Presentation of Infection in Older Adults. Infectious Disease Clinics of North America, 2017, 31, 593-608.	1.9	70
161	Clinical Variants of New Delhi Metallo-Î²-Lactamase Are Evolving To Overcome Zinc Scarcity. ACS Infectious Diseases, 2017, 3, 927-940.	1.8	49
162	Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from Î²-Lactamase Protein Engineering. MBio, 2017, 8, .	1.8	93

#	Article	IF	Citations
163	Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae â€“ Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 1020-1021.	4.6	10
164	Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE. MBio, 2017, 8, .	1.8	52
165	Nosocomial Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Isolates Containing bla _{OXA-237} Carried on a Plasmid. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	38
166	A general reaction mechanism for carbapenem hydrolysis by mononuclear and binuclear metallo-Î²-lactamases. Nature Communications, 2017, 8, 538.	5.8	98
167	Failure to Communicate: Transmission of Extensively Drug-Resistantbla_{OXA-237}-ContainingAcinetobacter baumanniiâ€”Multiple Facilities in Oregon, 2012â€“2014. Infection Control and Hospital Epidemiology, 2017, 38, 1335-1341.	1.0	17
168	Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	52
169	Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-Î²-lactamase-1. Journal of Medicinal Chemistry, 2017, 60, 7267-7283.	2.9	120
170	A 17-Year Nationwide Study of Burkholderia cepacia Complex Bloodstream Infections Among Patients in the United States Veterans Health Administration. Clinical Infectious Diseases, 2017, 65, 1327-1334.	2.9	27
171	Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis. Journal of Infectious Diseases, 2017, 216, 489-501.	1.9	67
172	Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III. Journal of Clinical Microbiology, 2017, 55, 134-144.	1.8	26
173	Î²-Lactamases: A Focus on Current Challenges. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a025239.	2.9	205
174	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum Î²-Lactamaseâ€“Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	2.9	43
175	A Prospective Observational Study of the Epidemiology, Management, and Outcomes of Skin and Soft Tissue Infections Due to Carbapenem-Resistant Enterobacteriaceae. Open Forum Infectious Diseases, 2017, 4, ofx157.	0.4	22
176	A Comparison of Molecular Typing Methods Applied to Enterobacter cloacae complex: hsp60 Sequencing, Rep-PCR, and MLST. Pathogens and Immunity, 2017, 2, 23.	1.4	7
177	Multidrug Resistant Pseudomonas aeruginosa Causing Prosthetic Valve Endocarditis: A Genetic-Based Chronicle of Evolving Antibiotic Resistance. Open Forum Infectious Diseases, 2016, 3, ofw188.	0.4	23
178	Epidemiology and Management of Skin and Soft Tissue Infection (SSTI) Due to Carbapenem-Resistant Enterobacteriaceae: A Report From The Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRaCKle). Open Forum Infectious Diseases, 2016, 3, .	0.4	0
179	Ceftazidime/Avibactam and Ceftolozane/Tazobactam in Treatment of Pulmonary Infections by Imipenem Resistant Pseudomonas aeruginosa. Open Forum Infectious Diseases, 2016, 3, .	0.4	1
180	Application of "Precision Medicine" Through the Molecular Characterization of Extensively Drug Resistant (XDR) Klebsiella pneumoniae in a Multivisceral Transplant Candidate. Open Forum Infectious Diseases, 2016, 3, .	0.4	1

#	Article	IF	Citations
181	Ceftolozane-Tazobactam (C/T) for Severe Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
182	Prosthetic Valve Endocarditis Caused by Bartonella henselae: A Case Report of Molecular Diagnostics Informing Nonsurgical Management. Open Forum Infectious Diseases, 2016, 3, ofw202.	0.4	3
183	A Change in Paradigm: Diabetes Exacerbates Infection Severity by Hyperinflammation, Not Immunosuppression. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
184	Carbapenem-Resistant Enterobacteriaceae in the Veterans Health Administration: A â€œSecond Epidemicâ€• of Carbapenem Resistance Among Enterobacter cloacae After That of Klebsiella pneumoniae. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
185	Fecal Contamination Contributes to the â€œResistomeâ€•of Urban Surface Waters in Northeast Brazil. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
186	Molecular Analysis of Colistin Resistance Among Klebsiella pneumoniae Producing K pneumoniae Carbapenemase: Heterogeneity of Genetic Mechanisms. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
187	A 17-Year Nationwide Study of Burkholderia cepacia Complex (Bcc) Blood Stream Infections (BSIs) Among Patients in the Veterans Health Administration (VHA). Open Forum Infectious Diseases, 2016, 3, .	0.4	0
188	Prosthetic Valve Endocarditis (PVE) Caused by Bartonella henselae: A Case Report of Molecular Methods to Diagnose and Inform Non-Surgical Management. Open Forum Infectious Diseases, 2016, 3, .	0.4	2
189	Burkholderia cepacia Bacteremias in a Bone Marrow Transplant Unit Associated with Contaminated Water Baths Used for Stem Cell Thawing. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
190	Describing Infections of the Spine Treated With Ceftaroline: The DISC Studyâ€”Preliminary Results. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
191	Bacterial Colonization and Antibiotic Resistance in a Prospective Cohort of Newborn Infants During the First Year of Life. Open Forum Infectious Diseases, 2016, 3, ofw221.	0.4	11
192	Analysis of Î²-Lactamase Resistance Determinants in Enterobacteriaceae from Chicago Children: a Multicenter Survey. Antimicrobial Agents and Chemotherapy, 2016, 60, 3462-3469.	1.4	33
193	Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). Clinical Infectious Diseases, 2016, 63, 812-817.	2.9	27
194	Overview: Global and Local Impact of Antibiotic Resistance. Infectious Disease Clinics of North America, 2016, 30, 313-322.	1.9	175
195	New Î²-Lactamase Inhibitors in the Clinic. Infectious Disease Clinics of North America, 2016, 30, 441-464.	1.9	138
196	Antibiotic Resistance in the Twenty-First Century: Current Concepts and Future Directions. Infectious Disease Clinics of North America, 2016, 30, xiii-xiv.	1.9	3
197	Membrane anchoring stabilizes and favors secretion of New Delhi metallo-Î²-lactamase. Nature Chemical Biology, 2016, 12, 516-522.	3.9	138
198	Initial Assessment of the Molecular Epidemiology of bla NDM-1 in Colombia. Antimicrobial Agents and Chemotherapy, 2016, 60, 4346-4350.	1.4	24

#	Article	IF	Citations
199	Mutations Decreasing Intrinsic Î²-Lactam Resistance Are Linked to Cell Division in the Nosocomial Pathogen Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2016, 60, 3751-3758.	1.4	20
200	Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation Î²-Lactam/Î²-Lactamase Inhibitor Combinations. Clinical Infectious Diseases, 2016, 63, 234-241.	2.9	433
201	LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48. Journal of Antimicrobial Chemotherapy, 2016, 71, 2171-2180.	1.3	27
202	A Multinational, Preregistered Cohort Study of Î²-Lactam/Î²-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-Î²-Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	1.4	137
203	First Report of a Verona Integron-Encoded Metallo-Î²-Lactamase-ProducingKlebsiella pneumoniaeInfection in a Child in the United States. Journal of the Pediatric Infectious Diseases Society, 2016, 5, e24-e27.	0.6	5
204	Molecular Diversity and Plasmid Analysis of KPC-Producing Escherichia coli. Antimicrobial Agents and Chemotherapy, 2016, 60, 4073-4081.	1.4	33
205	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	1.4	89
206	Successful Treatment of Bloodstream Infection Due to Metallo-Î²-Lactamase-Producing Stenotrophomonas maltophilia in a Renal Transplant Patient. Antimicrobial Agents and Chemotherapy, 2016, 60, 5130-5134.	1.4	61
207	Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: â€œWe're Gonna Need a Bigger Boatâ€• Clinical Infectious Diseases, 2016, 63, 1619-1621.	2.9	29
208	Multi-Center Study of the Molecular Epidemiology of Beta-Lactam Resistance in Enterobacteriaceae From Chicago Area Children: A Continuing Update. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
209	Ceftazidime-Avibactam for the Treatment of Post-Neurosurgical Meningitis Caused by a Klebsiella pneumoniae carbapenemase (KPC)-Producing Klebsiella pneumoniae. Open Forum Infectious Diseases, 2016, 3, .	0.4	11
210	Reply to Lesho and Clifford. Clinical Infectious Diseases, 2016, 63, 571-572.	2.9	1
211	Whole-Genome Comparative Analysis of Two Carbapenem-Resistant ST-258Klebsiella pneumoniaeStrains Isolated during a North-Eastern Ohio Outbreak: Differences within the High Heterogeneity Zones. Genome Biology and Evolution, 2016, 8, 2036-2043.	1.1	28
212	Cross-class metallo-Î²-lactamase inhibition by bisthiazolidines reveals multiple binding modes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E3745-54.	3.3	122
213	Risk Factors and Outcomes for Carbapenem-Resistant Klebsiella pneumoniae Isolation, Stratified by Its Multilocus Sequence Typing: ST258 Versus Non-ST258. Open Forum Infectious Diseases, 2016, 3, ofv213.	0.4	13
214	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	1.3	41
215	Genome dynamics of multidrug-resistant Acinetobacter baumannii during infection and treatment. Genome Medicine, 2016, 8, 26.	3.6	77
216	Membrane-Bound PenA Î²-Lactamase of Burkholderia pseudomallei. Antimicrobial Agents and Chemotherapy, 2016, 60, 1509-1514.	1.4	21

#	Article	IF	Citations
217	Boronic Acid Transition State Inhibitors Active against KPC and Other Class A Î²-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. Antimicrobial Agents and Chemotherapy, 2016, 60, 1751-1759.	1.4	49
218	Crystal Structures of KPC-2 and SHV-1 Î²-Lactamases in Complex with the Boronic Acid Transition State Analog S02030. Antimicrobial Agents and Chemotherapy, 2016, 60, 1760-1766.	1.4	36
219	SHV-129: A Gateway to Global Suppressors in the SHV Î²-Lactamase Family?. Molecular Biology and Evolution, 2016, 33, 429-441.	3.5	12
220	Exposing a Î²-Lactamase â€œTwistâ€• the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2016, 60, 777-788.	1.4	24
221	Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. Clinical Infectious Diseases, 2016, 62, 181-189.	2.9	52
222	Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods. Clinical Microbiology Reviews, 2016, 29, 1-27.	5.7	140
223	B1-Metallo-Î²-Lactamases: Where Do We Stand?. Current Drug Targets, 2016, 17, 1029-1050.	1.0	158
224	Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2015, 70, 1203-1211.	1.3	47
225	Host Fate is Rapidly Determined by Innate Effector-Microbial Interactions During Acinetobacter baumannii Bacteremia. Journal of Infectious Diseases, 2015, 211, 1296-305.	1.9	79
226	External guide sequence technology: a path to development of novel antimicrobial therapeutics. Annals of the New York Academy of Sciences, 2015, 1354, 98-110.	1.8	41
227	Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance. PLoS Computational Biology, 2015, 11, e1004493.	1.5	151
228	Inhibition of Klebsiella Î²-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. PLoS ONE, 2015, 10, e0136813.	1.1	67
229	Immunomodulatory Peptide IDR-1018 Decreases Implant Infection and Preserves Osseointegration. Clinical Orthopaedics and Related Research, 2015, 473, 2898-2907.	0.7	43
230	Are Staphylococcus intermedius Infections in Humans Cases of Mistaken Identity? A Case Series and Literature Review. Open Forum Infectious Diseases, 2015, 2, ofv110.	0.4	24
231	Avibactam and Inhibitor-Resistant SHV Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2015, 59, 3700-3709.	1.4	66
232	Variants of Î²-Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam. Antimicrobial Agents and Chemotherapy, 2015, 59, 3710-3717.	1.4	85
233	Bloodstream Infection Caused by Extended-Spectrum Â-Lactamase-Producing Gram-Negative Bacteria: How to Define the Best Treatment Regimen?. Clinical Infectious Diseases, 2015, 60, 1326-9.	2.9	21
234	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2015, 82, 65-69.	0.8	38

#	Article	IF	Citations
235	Complete Sequence of a bla _{KPC} -Harboring Cointegrate Plasmid Isolated from Escherichia coli. Antimicrobial Agents and Chemotherapy, 2015, 59, 2956-2959.	1.4	23
236	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2015, 59, 4375-4378.	1.4	24
237	Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1 Carbapenemase. ACS Infectious Diseases, 2015, 1, 544-554.	1.8	100
238	Click Chemistry in Lead Optimization of Boronic Acids as Î²-Lactamase Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 5445-5458.	2.9	39
239	Contamination of Ambient Air with Acinetobacter baumannii on Consecutive Inpatient Days. Journal of Clinical Microbiology, 2015, 53, 2346-2348.	1.8	18
240	Structural Basis of Activity against Aztreonam and Extended Spectrum Cephalosporins for Two Carbapenem-Hydrolyzing Class D Î²-Lactamases from Acinetobacter baumannii. Biochemistry, 2015, 54, 1976-1987.	1.2	31
241	First Report of an OXA-48-Producing Multidrug-Resistant Proteus mirabilis Strain from Gaza, Palestine. Antimicrobial Agents and Chemotherapy, 2015, 59, 4305-4307.	1.4	46
242	SISPA-Seq for rapid whole genome surveys of bacterial isolates. Infection, Genetics and Evolution, 2015, 32, 191-198.	1.0	16
243	Predominance of KPC-3 in a Survey for Carbapenemase-Producing Enterobacteriaceae in Portugal. Antimicrobial Agents and Chemotherapy, 2015, 59, 3588-3592.	1.4	41
244	Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV Î²-lactamases with single amino acid substitutions in the Î©-loop. Journal of Antimicrobial Chemotherapy, 2015, 70, 2279-2286.	1.3	105
245	In Vivo Evolution of CMY-2 to CMY-33 Î²-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime. Antimicrobial Agents and Chemotherapy, 2015, 59, 7483-7488.	1.4	17
246	ESBLs: An emerging problem in pediatric infectious diseases. Journal of Pediatric Infectious Diseases, 2015, 03, 217-220.	0.1	1
247	Performance of the CLSI Carba NP and the Rosco Carb Screen Assays Using North American Carbapenemase-Producing Enterobacteriaceae and Pseudomonas aeruginosa Isolates. Journal of Clinical Microbiology, 2015, 53, 3370-3373.	1.8	14
248	Elucidating the Role of Residue 67 in IMP-Type Metallo-Î²-Lactamase Evolution. Antimicrobial Agents and Chemotherapy, 2015, 59, 7299-7307.	1.4	19
249	Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2015, 59, 1020-1029.	1.4	121
250	Genomic and Transcriptomic Analyses of Colistin-Resistant Clinical Isolates of Klebsiella pneumoniae Reveal Multiple Pathways of Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 536-543.	1.4	185
251	Penam Sulfones and Î²-Lactamase Inhibition: SA2-13 and the Importance of the C2 Side Chain Length and Composition. PLoS ONE, 2014, 9, e85892.	1.1	9
252	960The Molecular Characterization of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenem-Resistant Enterobacteriaceae (CRE) in Chicago Children, a two center study. Open Forum Infectious Diseases, 2014, 1, S279-S280.	0.4	0

#	Article	IF	Citations
253	Culture negative empyema in a critically ill child: an opportunity for rapid molecular diagnostics. BMC Anesthesiology, 2014, 14, 107.	0.7	3
254	Host-Specific Enzyme-Substrate Interactions in SPM-1 Metallo-Î²-Lactamase Are Modulated by Second Sphere Residues. PLoS Pathogens, 2014, 10, e1003817.	2.1	32
255	The Deadly Impact of Extreme Drug Resistance in Acinetobacter baumannii*. Critical Care Medicine, 2014, 42, 1289-1291.	0.4	43
256	Genome Sequences of Two Carbapenemase-Resistant Klebsiella pneumoniae ST258 Isolates. Genome Announcements, 2014, 2, .	0.8	10
257	Population Structure of KPC-Producing Klebsiella pneumoniae Isolates from Midwestern U.S. Hospitals. Antimicrobial Agents and Chemotherapy, 2014, 58, 4961-4965.	1.4	78
258	Biochemical and Structural Analysis of Inhibitors Targeting the ADC-7 Cephalosporinase of Acinetobacter baumannii. Biochemistry, 2014, 53, 7670-7679.	1.2	32
259	The Different Inhibition Mechanisms of OXA-1 and OXA-24 Î²-Lactamases Are Determined by the Stability of Active Site Carboxylated Lysine. Journal of Biological Chemistry, 2014, 289, 6152-6164.	1.6	22
260	Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4988-4993.	3.3	325
261	Outcomes of carbapenem-resistant Enterobacteriaceae isolation: Matched analysis. American Journal of Infection Control, 2014, 42, 612-620.	1.1	43
262	New Î²-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World. Antimicrobial Agents and Chemotherapy, 2014, 58, 1835-1846.	1.4	258
263	Biochemical, Mechanistic, and Spectroscopic Characterization of Metallo-Î²-lactamase VIM-2. Biochemistry, 2014, 53, 7321-7331.	1.2	57
264	Antibiotic-Resistant Gram-Negative Bacterial Infections in Patients With Cancer. Clinical Infectious Diseases, 2014, 59, S335-S339.	2.9	93
265	Surveillance of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular Epidemiology and Outcomes through a Regional Network. Antimicrobial Agents and Chemotherapy, 2014, 58, 4035-4041.	1.4	132
266	Epithelial Innate Immune Response to Acinetobacter baumannii Challenge. Infection and Immunity, 2014, 82, 4458-4465.	1.0	23
267	A fluorescent carbapenem for structure function studies of penicillin-binding proteins, Î²-lactamases, and Î²-lactam sensors. Analytical Biochemistry, 2014, 463, 70-74.	1.1	17
268	Identification of Occult Fusobacterium nucleatum Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry. Journal of Clinical Microbiology, 2014, 52, 3462-3464.	1.8	9
269	Extensively Drug-Resistant Pseudomonas aeruginosa Isolates Containing bla _{VIM-2} and Elements of Salmonella Genomic Island 2: a New Genetic Resistance Determinant in Northeast Ohio. Antimicrobial Agents and Chemotherapy, 2014, 58, 5929-5935.	1.4	34
270	Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding. Trends in Microbiology, 2014, 22, 686-696.	3.5	407

#	Article	IF	Citations
271	Reclaiming the Efficacy of Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations: Avibactam Restores the Susceptibility of CMY-2-Producing Escherichia coli to Ceftazidime. Antimicrobial Agents and Chemotherapy, 2014, 58, 4290-4297.	1.4	35
272	New Insights into Dissemination and Variation of the Health Care-Associated Pathogen Acinetobacter baumannii from Genomic Analysis. MBio, 2014, 5, e00963-13.	1.8	184
273	Crystal Structure of Mox-1, a Unique Plasmid-Mediated Class C Î²-Lactamase with Hydrolytic Activity towards Moxalactam. Antimicrobial Agents and Chemotherapy, 2014, 58, 3914-3920.	1.4	7
274	Multiplex PCR for Identification of Two Capsular Types in Epidemic KPC-Producing Klebsiella pneumoniae Sequence Type 258 Strains. Antimicrobial Agents and Chemotherapy, 2014, 58, 4196-4199.	1.4	25
275	Ureaplasma parvum Prosthetic Joint Infection Detected by PCR. Journal of Clinical Microbiology, 2014, 52, 2248-2250.	1.8	19
276	Direct Detection of Indirect Transmission of Streptobacillus moniliformis Rat Bite Fever Infection. Journal of Clinical Microbiology, 2014, 52, 2259-2261.	1.8	12
277	Infections caused by fluoroquinolone-resistant Escherichia coli following transrectal ultrasound-guided biopsy of the prostate. Journal of Global Antimicrobial Resistance, 2014, 2, 71-76.	0.9	11
278	Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infectious Diseases, The, 2013, 13, 785-796.	4.6	1,328
279	Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease, 2013, 77, 179-194.	0.8	74
280	Acinetobacter baumannii rOmpA vaccine dose alters immune polarization and immunodominant epitopes. Vaccine, 2013, 31, 313-318.	1.7	72
281	â€œAirborne Assaultâ€• Critical Care Medicine, 2013, 41, 2042-2044.	0.4	29
282	First Clinical Cases of OXA-48-Producing Carbapenem-Resistant Klebsiella pneumoniae in the United States: the â€œMenaceâ€•Arrives in the New World. Journal of Clinical Microbiology, 2013, 51, 680-683.	1.8	88
283	Insights into Î²-Lactamases from Burkholderia Species, Two Phylogenetically Related yet Distinct Resistance Determinants. Journal of Biological Chemistry, 2013, 288, 19090-19102.	1.6	47
284	â€œStormy waters aheadâ€• global emergence of carbapenemases. Frontiers in Microbiology, 2013, 4, 48.	1.5	356
285	Draft Genome Sequence of the Clinical Isolate Acinetobacter nosocomialis Strain M2. Genome Announcements, 2013, 1, .	0.8	42
286	Novel Î²-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Frontiers in Microbiology, 2013, 4, 392.	1.5	59
287	Understanding the Molecular Determinants of Substrate and Inhibitor Specificities in the Carbapenemase KPC-2: Exploring the Roles of Arg220 and Glu276. Antimicrobial Agents and Chemotherapy, 2012, 56, 4428-4438.	1.4	51
288	Exploring the Role of a Conserved Class A Residue in the Î©-Loop of KPC-2 Î²-Lactamase. Journal of Biological Chemistry, 2012, 287, 31783-31793.	1.6	84

#	Article	IF	Citations
289	Crystal Structures of KPC-2 Î²-Lactamase in Complex with 3-Nitrophenyl Boronic Acid and the Penam Sulfone PSR-3-226. Antimicrobial Agents and Chemotherapy, 2012, 56, 2713-2718.	1.4	46
290	Inhibition of LpxC Protects Mice from Resistant Acinetobacter baumannii by Modulating Inflammation and Enhancing Phagocytosis. MBio, 2012, 3, .	1.8	126
291	Early Insights into the Interactions of Different Î²-Lactam Antibiotics and Î²-Lactamase Inhibitors against Soluble Forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3. Antimicrobial Agents and Chemotherapy, 2012, 56, 5687-5692.	1.4	33
292	Detection of Extended-Spectrum Î²-Lactamase and Klebsiella pneumoniae Carbapenemase Genes Directly from Blood Cultures by Use of a Nucleic Acid Microarray. Journal of Clinical Microbiology, 2012, 50, 2901-2904.	1.8	25
293	"Silent" Dissemination of Klebsiella pneumoniae Isolates Bearing K. pneumoniae Carbapenemase in a Long-term Care Facility for Children and Young Adults in Northeast Ohio. Clinical Infectious Diseases, 2012, 54, 1314-1321.	2.9	73
294	Active and Passive Immunization Protects against Lethal, Extreme Drug Resistant-Acinetobacter baumannii Infection. PLoS ONE, 2012, 7, e29446.	1.1	147
295	Carbapenems: Past, Present, and Future. Antimicrobial Agents and Chemotherapy, 2011, 55, 4943-4960.	1.4	1,053
296	Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC Î²â€lactamase. Protein Science, 2011, 20, 941-958.	3.1	42
297	Ligand-Dependent Disorder of the Î© Loop Observed in Extended-Spectrum SHV-Type Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2011, 55, 2303-2309.	1.4	24
298	Extended-Spectrum AmpC Cephalosporinase in Acinetobacter baumannii: ADC-56 Confers Resistance to Cefepime. Antimicrobial Agents and Chemotherapy, 2011, 55, 4922-4925.	1.4	66
299	Increasing prevalence and dissemination of NDM-1 metallo-Â-lactamase in India: data from the SMART study (2009). Journal of Antimicrobial Chemotherapy, 2011, 66, 1992-1997.	1.3	143
300	Elucidating the role of Trp105 in the KPCâ€2 Î²â€lactamase. Protein Science, 2010, 19, 1714-1727.	3.1	57
301	Evaluation of Updated Interpretative Criteria for Categorizing Klebsiella pneumoniae with Reduced Carbapenem Susceptibility. Journal of Clinical Microbiology, 2010, 48, 4417-4425.	1.8	48
302	Inhibitor Resistance in the KPC-2 Î²-Lactamase, a Preeminent Property of This Class A Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2010, 54, 890-897.	1.4	161
303	Substrate Selectivity and a Novel Role in Inhibitor Discrimination by Residue 237 in the KPC-2 Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2010, 54, 2867-2877.	1.4	53
304	Genetic Factors Associated with Elevated Carbapenem Resistance in KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2010, 54, 4201-4207.	1.4	129
305	Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. Journal of Antimicrobial Chemotherapy, 2010, 65, 1807-1818.	1.3	176
306	Penicillin Sulfone Inhibitors of Class D Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2010, 54, 1414-1424.	1.4	42

#	Article	IF	Citations
307	Inhibition of the Class C Î²-Lactamase from Acinetobacter spp.: Insights into Effective Inhibitor Design. Biochemistry, 2010, 49, 329-340.	1.2	40
308	Design, Synthesis, and Crystal Structures of 6-Alkylidene-2â€²-Substituted Penicillanic Acid Sulfones as Potent Inhibitors of Acinetobacter baumannii OXA-24 Carbapenemase. Journal of the American Chemical Society, 2010, 132, 13320-13331.	6.6	60
309	Three Decades of Î²-Lactamase Inhibitors. Clinical Microbiology Reviews, 2010, 23, 160-201.	5.7	1,356
310	Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. Journal of Antimicrobial Chemotherapy, 2009, 63, 427-437.	1.3	194
311	Identification of Plasmid-Mediated AmpC Î²-Lactamases in Escherichia coli , Klebsiella spp., and Proteus Species Can Potentially Improve Reporting of Cephalosporin Susceptibility Testing Results. Journal of Clinical Microbiology, 2009, 47, 294-299.	1.8	38
312	Resistance to Colistin in Acinetobacter baumannii Associated with Mutations in the PmrAB Two-Component System. Antimicrobial Agents and Chemotherapy, 2009, 53, 3628-3634.	1.4	426
313	Performance of the Phoenix bacterial identification system compared with disc diffusion methods for identifying extended-spectrum Î²-lactamase, AmpC and KPC producers. Journal of Medical Microbiology, 2009, 58, 774-778.	0.7	17
314	Why are we afraid of Acinetobacter baumannii?. Expert Review of Anti-Infective Therapy, 2008, 6, 269-271.	2.0	47
315	Inhibition of OXA-1 Î²-Lactamase by Penems. Antimicrobial Agents and Chemotherapy, 2008, 52, 3135-3143.	1.4	33
316	Comparative Genome Sequence Analysis of Multidrug-Resistant Acinetobacter baumannii. Journal of Bacteriology, 2008, 190, 8053-8064.	1.0	429
317	Inhibition of Class A Î²-Lactamases by Carbapenems: Crystallographic Observation of Two Conformations of Meropenem in SHV-1. Journal of the American Chemical Society, 2008, 130, 12656-12662.	6.6	69
318	Isolation and Characterization of an Autoinducer Synthase from Acinetobacter baumannii. Journal of Bacteriology, 2008, 190, 3386-3392.	1.0	243
319	The role of OXA-1 Î²-lactamase Asp66 in the stabilization of the active-site carbamate group and in substrate turnover. Biochemical Journal, 2008, 410, 455-462.	1.7	22
320	Global Challenge of Multidrug-ResistantAcinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2007, 51, 3471-3484.	1.4	1,027
321	Crystal Structure of KPC-2:â€‰ Insights into Carbapenemase Activity in Class A Î²-Lactamases,. Biochemistry, 2007, 46, 5732-5740.	1.2	109
322	Topical triple-antibiotic ointment as a novel therapeutic choice in wound management and infection prevention: a practical perspective. Expert Review of Anti-Infective Therapy, 2007, 5, 773-782.	2.0	27
323	Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa. Clinical Infectious Diseases, 2006, 43, S49-S56.	2.9	558
324	Analysis of Antibiotic Resistance Genes in Multidrug-Resistant Acinetobacter sp. Isolates from Military and Civilian Patients Treated at the Walter Reed Army Medical Center. Antimicrobial Agents and Chemotherapy, 2006, 50, 4114-4123.	1.4	457

#	Article	IF	Citations
325	Role of Asp104 in the SHV Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2006, 50, 4124-4131.	1.4	32
326	Multiple Substitutions at Ambler Position 244 in SHV Provide Insight Into Importance of Arg244 in Inhibitor and Substrate Binding. FASEB Journal, 2006, 20, A896.	0.2	0
327	Identification of a New Allelic Variant of the Acinetobacter baumannii Cephalosporinase, ADC-7 Î²-Lactamase: Defining a Unique Family of Class C Enzymes. Antimicrobial Agents and Chemotherapy, 2005, 49, 2941-2948.	1.4	131
328	Ultrahigh Resolution Structure of a Class A Î²-Lactamase: On the Mechanism and Specificity of the Extended-spectrum SHV-2 Enzyme. Journal of Molecular Biology, 2003, 328, 289-301.	2.0	113
329	Resistant Pathogens in Respiratory Tract Infections in Older People. Journal of the American Geriatrics Society, 2002, 50, 236-241.	1.3	17
330	Inactivation of CMY-2 Î²-lactamase by tazobactam: initial mass spectroscopic characterization. BBA - Proteins and Proteomics, 2001, 1547, 196-205.	2.1	25
331	Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 Î²-lactamase, an SHV-family class A enzyme. Biochemical Journal, 1998, 333, 395-400.	1.7	29
332	Charles C. J. Carpenter Jr (1931â€“2020). Journal of Infectious Diseases, 0, , .	1.9	0
333	Overview of Aminoglycosides and Enzyme-Mediated Bacterial Resistance, Clinical Implications. , 0, , 1-6.		0
334	Penicillanic Acid Sulfones Inactivate the Extended-Spectrum Î²-Lactamase CTX-M-15 through Formation of a Serine-Lysine Cross-Link: an Alternative Mechanism of Î²-Lactamase Inhibition. MBio, 0, , .	1.8	2
335	Association of Kidney Comorbidities and Acute Kidney Failure With Unfavorable Outcomes After COVID-19 in Individuals With the Sickle Cell Trait. JAMA Internal Medicine, 0, , .	2.6	15
336	Zidebactam restores sulbactam susceptibility against carbapenem-resistant Acinetobacter baumannii isolates. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	2